Cyclerion Therapeutics, Inc. (CYCN): Price and Financial Metrics
GET POWR RATINGS... FREE!
CYCN Stock Summary
- The ratio of debt to operating expenses for CYCLERION THERAPEUTICS INC is higher than it is for about just 0.48% of US stocks.
- With a year-over-year growth in debt of -100%, CYCLERION THERAPEUTICS INC's debt growth rate surpasses just 0% of about US stocks.
- Revenue growth over the past 12 months for CYCLERION THERAPEUTICS INC comes in at -56.25%, a number that bests merely 3.37% of the US stocks we're tracking.
- Stocks that are quantitatively similar to CYCN, based on their financial statements, market capitalization, and price volatility, are FDMT, EDIT, RARE, MRUS, and DTIL.
- CYCN's SEC filings can be seen here. And to visit CYCLERION THERAPEUTICS INC's official web site, go to www.cyclerion.com.
CYCN Valuation Summary
- In comparison to the median Healthcare stock, CYCN's EV/EBIT ratio is 101.97% lower, now standing at -0.2.
- Over the past 47 months, CYCN's EV/EBIT ratio has gone up 1.5.
Below are key valuation metrics over time for CYCN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CYCN | 2023-01-30 | 17.9 | 1.7 | -0.6 | -0.2 |
| CYCN | 2023-01-27 | 18.8 | 1.8 | -0.6 | -0.2 |
| CYCN | 2023-01-26 | 19.4 | 1.8 | -0.6 | -0.2 |
| CYCN | 2023-01-25 | 17.2 | 1.6 | -0.6 | -0.1 |
| CYCN | 2023-01-24 | 17.7 | 1.7 | -0.6 | -0.1 |
| CYCN | 2023-01-23 | 19.0 | 1.8 | -0.6 | -0.2 |
CYCN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CYCN has a Quality Grade of C, ranking ahead of 48.21% of graded US stocks.
- CYCN's asset turnover comes in at 0.034 -- ranking 346th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows CYCN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.034 | 1 | -0.991 |
| 2021-03-31 | 0.011 | 1 | -0.741 |
| 2020-12-31 | 0.018 | 1 | -0.770 |
| 2020-09-30 | 0.025 | 1 | -0.733 |
| 2020-06-30 | 0.028 | 1 | -0.734 |
| 2020-03-31 | 0.029 | 1 | -0.788 |
CYCN Price Target
For more insight on analysts targets of CYCN, see our CYCN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $4.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
CYCN Stock Price Chart Interactive Chart >
CYCN Price/Volume Stats
| Current price | $0.73 | 52-week high | $1.45 |
| Prev. close | $0.64 | 52-week low | $0.35 |
| Day low | $0.64 | Volume | 488,590 |
| Day high | $0.80 | Avg. volume | 109,391 |
| 50-day MA | $0.67 | Dividend yield | N/A |
| 200-day MA | $0.69 | Market Cap | 31.96M |
Cyclerion Therapeutics, Inc. (CYCN) Company Bio
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Latest CYCN News From Around the Web
Below are the latest news stories about CYCLERION THERAPEUTICS INC that investors may wish to consider to help them evaluate CYCN as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to start the day with an overview of the biggest pre-market stock movers traders need to know about for Tuesday morning! |
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The CompanyCAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company acting solely by all of its independent and disinterested members (the “Independent Board”) has reviewed the non-binding and unsolicited proposal received on November 20, 2022, from a group that includes the Company’s chief executive officer, to among other things purchase certain assets of the Company. After consultation with its legal and fi |
Cyclerion Therapeutics Third Quarter 2022 Earnings: US$0.24 loss per share (vs US$0.26 loss in 3Q 2021)Cyclerion Therapeutics ( NASDAQ:CYCN ) Third Quarter 2022 Results Key Financial Results Net loss: US$10.5m (loss... |
Cyclerion Therapeutics lays off nearly half of workforceCyclerion Therapeutics Inc. is culling its workforce as it narrows its focus to mitochondrial diseases. |
Cyclerion Shares Fall After Reprioritized Pipeline, Workforce ReductionCyclerion Therapeutics Inc (NASDAQ: CYCN) is reprioritizing development programs and focusing resources and capabilities on candidates for mitochondrial diseases. The company has been exploring the pharmacology of sGC stimulation with once-daily CY6463 in signal-seeking studies in three patient populations. From now on, Cyclerion will focus future development of CY6463 concentrating first on the development of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). "W |
CYCN Price Returns
| 1-mo | 8.97% |
| 3-mo | 69.77% |
| 6-mo | -18.90% |
| 1-year | -44.27% |
| 3-year | -77.95% |
| 5-year | N/A |
| YTD | 11.25% |
| 2022 | -61.85% |
| 2021 | -43.79% |
| 2020 | 12.50% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...